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Jean Sanders and colleagues at theFredHutchinson
Cancer Research Center reported in 1985 that sibling
donor transplant in first remission is the optimal treat-
ment for childhood acuty myelogenous leukemia
(AML), with disease-free survival of 64%, and excellent
quality of life [1]. This seminal observation remains
largely, although not entirely, true 26 years later. Cur-
rent movement in the application of transplant in
AML is in 2 contrasting directions. Physicians are
now withholding transplant from children with very
good-risk disease, and trying to use transplant earlier
in children with the highest risk disease.
Over the last quarter century important progress has
beenmade in theuseof chemotherapy forAML, in series
of randomized clinical trials conducted by cooperative
groups in the United States, Europe, and elsewhere.
The key strategies that have improved survival with che-
motherapy are successful dose intensification,madepos-
sible with improved aggressive supportive care and
improved risk group assignment. Improvements in che-
motherapy and in risk assignment now allow us to iden-
tify children with favorable biology (those with t[8:21],
or inversion 16) for whom allogeneic transplant in first
complete remission (CR1) is unnecessary [2,3].
A key achievement in the last 25 years has been the
easy availability of well-matched unrelated donors
from well-integrated registries, and of banks of frozen
cord blood [4,5]. Many studies now report that results
comparable to those seen with sibling donors can be
achieved with unrelated donor stem cells, and this
extends availability of transplant to many more
children. These advances are remarkable, and yet
there remains significant room for improvement in
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considerable. Moreover, it remains unclear if
children with the highest risk disease benefit from
transplantation, and efforts are currently being made
to answer these questions. This presentation will
focus on potential strategies to further improve
transplant outcomes in cases with high-risk AML.IDENTIFICATION OF HIGHEST RISK
PATIENTS
Ourapproach that shouldbeconsidered for stemcell
transplantation in firstCRhas evolved over the last 2 de-
cades.Woods et al. [6,7] demonstrated that patientswho
received an allogeneic stem cell transplantation from
a matched family donor in first CR had an improved
outcome compared with conventional chemotherapy.
As a result of this study, stem cell transplantation
(SCT) from an HLA matched family donor in first CR
became the standard of care for treatment of childhood
AML. As patients with 27 and 25/del5q were found
to have an extremely poor outcome with conventional
chemotherapy, more recent trials allocated this small
cohort of high-risk patients to SCT from the most suit-
able donors.Further, patientswith favorable risk cytoge-
netics (Core Binding Factor AML), were shown to have
similar outcomes regardless of whether they are treated
with chemotherapy or SCT. Thus, those with Core
Binding Factor AML would not receive an allogeneic
SCT in first CR even if a matched donor was available.
In this 3-tier risk-based therapy allocation, 5% to 10%
of the patients would be considered high risk, 20%
would be in the favorable risk category, and themajority
of patients would remain in the standard risk category
and would receive SCT in first CR if a matched family
donor was available. More recently, several AML-
associated mutations were correlated with clinical
outcome, thus expanding the risk cohorts for therapy
allocation. Mutations in the NPM and CEBPA genes
are shown to be associated with improved clinical out-
come [8,9] and those with FLT3/ITD associated with
poor outcome with conventional chemotherapy [10].
Addition of these mutations increased high- and low-
risk cohorts by 10% each, and the standard-risk cohort
remained at nearly 65%.Multidimensional flow cytom-
etry (MDF) has been used to define relapse risk in those
without known cytogenetic ormolecularmarkers.COGS33
Figure 1. Two-tier risk allocation schema. Presence of residual disease at the end of induction is associated with relapse and poor outcome in standard
risk, but not in the high- or low-risk patients. Addition of MDF data in SR cohort to the previously known cytogenetics/molecular prognostic data allows
generation of 2-tier schema that allows risk appropriate allocation of SCT in first CR.
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cytogenetics characteristics, mutation profile (FLT3/
ITD, CEBPA, and NPM mutation status), and MDF
data, and demonstrated that in patients without known
molecular prognostic markers (standard-risk [SR]
cohort), MDF was able to identify presence of minimal
residual disease (MRD) in nearly 30% of patients. In
this SR cohort, those with MRD after induction had
a significantly worse survival than those who did not
have evidence of MRD by MDF (26% versus 67%).
This study also demonstrated that presence of MRD in
those with high-risk or low-risk disease was not associ-
ated with outcome [11]. As a result, a novel 2-tier
risk-based allocation systemhas beendevised and imple-
mented into the COG AML trials, where those with
either high-risk cytogenetic and molecular features or
thosewith otherwise SRdiseasewithMRDare allocated
to the high-risk arm of the study and receive SCT from
the most suitable donor in first CR. The remaining
patients, those with favorable cytogenetics/mutations
or the MRD-negative SR cohort are considered favor-
able risk and would not receive SCT in first CR regard-
less of availability of matched family donors (Figure 1).
Cytogenetics, molecular genotyping, and postin-
ductionMDF analysis provide a robust means of strat-
ifying all pediatric patients with AML into 2 risk
groups with significantly different outcomes. This
novel risk-based approach enables assignment of
SCT to those at highest risk of relapse who may
most benefit from this aggressive management.APPROACHES TO IMPROVING OUTCOMES:
SELECTION OF OPTIMAL DONORS
Seventeen percent of children with AML and
primary induction failure were long-term survivors in
a report describing unrelated donor transplants forAML [12]. These data suggest that this small subset
of children who were clearly refractory to chemother-
apy achieved disease control from the presence of allo-
geneic cells. This raises the tantalizing prospect that if
we knew how to select the optimal donor we would be
able to control disease easily in all children with refrac-
tory disease.The use of killer cell immunoglobulin-like
receptor (KIR)mismatch to select donors that are likely
to control disease without causing fulminant graft-
versus-host disease (GVHD) has been proposed and
supported bymousemodels and some, but not all, clin-
ical data [13-19]. The validity of this strategy, and the
optimal way to examine KIR genotype and phenotype
to make the donor selection, remain controversial
[20-22]. A prospective COG study is seeking to
address this issue prospectively, asking whether it is
feasible to obtain KIR typing in a timely manner for
unrelated donor and cord blood transplants, and
whether outcomes are improved.
About half of all transplants for pediatric leukemia
now use cord blood as a stem cell source. Preliminary
studies from the University of Minnesota suggest that
relapse is reduced in recipients of double cord blood
transplants, compared with single-unit transplanta-
tions, and this question is being addressed by the
bone marrow transplant clinical trials network in
a prospective randomized trial, close to completion
of accrual [23].APPROACHES TO IMPROVING OUTCOMES:
IS THERE BENEFIT TO IRRADIATION OR
INCREASING DOSE INTENSITY?
Busulfan (Bu) and cyclophosphamide (Cy) as pre-
parative therapy has become a standard approach to
transplant for children with AML, and the availability
of intravenous busulfan has facilitated this treatment.
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for disease control remains an issue, as the focus of
transplantation is increasingly on control of high-risk
disease. Four largely adult randomized trials compar-
ing Bu/Cy with total-body irridiation (TBI) have
shown no statistically significant difference in survival
[24]. Similarly, a European Bone and Marrow Trans-
plant (EBMT) comparison of outcomes reported to
their registry also showed similar outcomes with
Bu/Cy or Cy/TBI [25]. Similar pediatric registry or
prospective studies are not available so some uncer-
tainty remains, but the increased adverse effects associ-
ated with use of TBI in young children, and the
absence of compelling data suggesting improved
disease control in the adult studies limit enthusiasm.
A number of studies, most conducted some years
ago, have sought to add additional chemotherapy to
TBI, increased the dose of TBI, or replaced cyclophos-
phamide with an alternative alkylating agent [26,27].
None of these studies showed improved survival,
with the majority showing modest reduction in
relapse offset by increased treatment-related mortality
(TRM), suggesting little yield from intensification of
the preparative regimen.APPROACHES TO IMPROVING
OUTCOMES—DOES REDUCING THE
INTENSITYOF THE PREPARATIVE REGIMEN
MAKE SENSE FOR PEDIATRIC AML?
The use of reduced-intensity conditioning (RIC)
regimens for older adults with AML has been an
important advance, and has extended transplantation
to persons typically thought ineligible. A number of
authors have sought to compare these 2 strategies,
generally in a retrospective nonrandomized manner,
and generally the data have shown comparable survival,
with reduced TRM but increased relapse in the
recipients of the lower intensity preparative regi-
men [28,29]. In pediatric transplantation TRM is
commonly lower than in adult studies, and the
opportunity for improvement is therefore less. Data
from National Marrow Donor Program show that
TRM for children receiving unrelated donor
transplant for acute leukemia has been cut in half in
the last 10 years to 15%, likely as a consequence of
improved HLA typing, larger donor pools for
selection and improved supportive care [30,31]. In
contrast, relapse rates have increased, suggesting that
children with more aggressive leukemia are coming to
transplant, and that a focus on improved disease
control is more likely to improve outcomes than
attempts to reduce TRM. Similarly, TRM for
matched sibling donor bone marrow transplantation in
CR1 for children transplanted in CR1 between 2006
and 2010 (n 5 130) is 3% at day 100 and 6% at 1 year
(personal communication from Mary Eapen, Centerfor International Blood and Marrow Transplant
Research), so substituting reduced intensity for
myeloablative transplant in the ‘‘upfront’’ setting could
have only a modest effect on overall outcome.
Despite the low TRM seen in children reaching
transplant, chemotherapy for AML is typically aggres-
sive, and significant infections and impairments in
organ function can arise and make fully ablative trans-
plant risky. Reduced-intensity transplant may allow at
least some of those children to be transplanted. It is
important, however, to consider the data from such
transplants critically. Getting a child to transplant at
all costs only makes sense if we are sure that outcomes
will be improved, and these data are currently lacking
for children with biologically aggressive disease.
Indeed, data from a combined analysis of transplanta-
tion of children with AML registered on a series of
cooperative group studies did not show a survival
advantage for children who managed to get to trans-
plant, although this study included a relatively small
number of transplants performed over a period of
many years (26) [32].APPROACHES TO IMPROVING OUTCOMES:
GETTING CHILDREN TOTRANSPLANT:
HYPOMETHYLATING AGENTS, AND NOVEL
SMALL MOLECULES
Many children with high-risk AMLwill fail early in
the course of treatment, dying early of toxicity (gener-
ally infection) or of refractory disease. Similarly, trans-
plant studies of children with relapsed disease show
50% survival for those in second remission but fail to
take into account childrenwho never achieved a second
remission, died of toxicity before remission, or entered
remission with such severe organ dysfunction or infec-
tion they were not candidates for transplant. Newer
chemotherapy agents such as decitabine or azacytidine
offer alternative pathways to disease control with
reduced toxicity and can facilitate transplant with
a good performance status. Prospective studies are
open in Cincinnati and in adult centers, offering
a newer strategy that may be particularly applicable
to biologically high-risk disease. Similarly, tyrosine
kinase inhibitors and other small molecules are being
tested, for example, Sorafenib for AML with FlT3-
ITD. Incorporation of novel agents into pre- or post-
transplant treatments may improve survival, and offers
an attractive alternative to the successful but perhaps
exhausted strategy of dose intensification using
well-understood cytotoxic chemotherapy agents.PREVENTION AND MANAGEMENT
OF POSTTRANSPLANTAML RELAPSE
Relapse is themajor cause of treatment failure after
hematopoietic cell transplantation (HCT) for AML.
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(.5% blasts) eventually succumb to their disease
because posttransplant relapse therapies have been
largely inadequate. An ongoing focus is to define ear-
lier relapse thresholds based on sensitive techniques.
The hypothesis is that interventions to treat MRD be-
fore morphologic relapse might mitigate the poor
prognosis conferred by ‘‘MRD positive’’ (MRD1).
Among several MRD monitoring parameters, MDF
is the most broadly applicable technology that is avail-
able. MRD1 can be further delineated when other
data are available. For example, disease-specific molec-
ular markers, or serial chimerism studies that show
declining donor hematopoeisis, particularly if lineage
specific cell populations (eg, CD341) are analyzed
[33,34]. Unfortunately, well-designed published inter-
vention studies addressing AML relapse or MRD1
states before and after HCT, are lacking.Wewill focus
on frequently asked questions about posttransplant
relapse, whether MRD or morphologic relapse. A
major caveat is that published intervention studies
are retrospective, they suffer from selection bias,
including time from HCT, tempo of relapse, sites of
relapse, performance status, to list just a few.
How to React to MRD1AML Immediately
before HCT?
The decision to proceed in AML toward HCT
relies heavily on the prognostic combination of well-
described cytogenetic and molecular risk factors,
patient performance status, and donor availability.
Recently added to decision making for patients in mor-
phologic CR is their end of induction and pretransplant
MRD status. Walter et al. [35] recently showed that
based on pretransplant MDF data, the 2-year survival
for those with MRD immediately before HCT was
30% compared with that of 77% for MRD2 patients.
Similar findings were observed in children (15% versus
67%) [36]. One obvious approach is to try to reverse
MRD1 status with additional chemotherapy. Unfortu-
nately, the desired goal ofMRD2may bemet with fur-
ther rise inMRD.Studies are needed to testwhether the
poor prognosis conferred byMRD1AML is reversible
even when MRD2 is achieved. A valid concern is that
cumulative toxicities and infections during chemother-
apy attempts may increase transplant-relatedmortality.
In this regard, it is worth remembering that among
a large cohort of AMLpatients whowere either inmor-
phologic relapse or with primary induction failure,
a 0 to$3 point score based on 5 adverse pre-HCT vari-
ables (first CR \6 months, circulating blasts, donor
other than HLA-sibling or well-matched unrelated,
Karnofsky Performance Scale/Lansky play perfor-
mance status (LPP)S\90, and poor-risk cytogenetics)
was able to delineate risk groups with 3- year survival
ranging from 6% to as high as 42% [37]. Therefore, al-
though pretransplant MRD1 associates with inferiorsurvival, not getting to HCT as a result of failed at-
tempts to convertMRD1 toMRD2 likely reduces sur-
vival potential to 0%!
Can Conditioning be Augmented to Minimize
Relapse?
One obvious strategy to combat posttransplant
relapse is to augment conditioning in those at high
risk of posttransplant relapse. Relapse rates decline
when TBI doses are escalated but associated increases
in nonrelapse mortality limit survival [27]. However,
radiolabeled monoclonal antibodies that target radia-
tion to hematopoietic tissues have been combined
safely with RIC and show promising results [38].
The augmentation of a standard fludarabine (FLU)/
Bu/antithymocyte globulin RIC with just 4 Gy TBI
was shown also to lower relapse rates [39]. Recently,
other groups also seeking to enhance the antileukemia
effect of RIC have explored whether replacing FLU
with clofarabine is beneficial and early data indicates
excellent engraftment rates, reasonable safety, and
promising efficacy in advanced AML [40,41].
What about Posttransplant Relapse
Chemoprophylaxis?
Tyrosine kinase inhibitors have been used in BCR/
ABL1 leukemias after HCT. Unfortunately, there is
a paucity of available agents that target AML. Such
agents should have drug interaction and toxicity pro-
files that are conducive to being used early after
HCT. An unresolved but testable question is whether
this approach should be used as prophylaxis in high
risk, or preemptively in all, based on the earliest detec-
tion ofMRD.Hypomethylating agents have been con-
sidered like low dose 5-azacitidine [42], which also has
activity in childhood AML [43]. The FLT3 inhibitor
sorafenib has been used in a small number of adults
and children to prevent or treat MRD or frank relapse
of FLT3 ITD mutated AML after HCT with a few
notable CRs [44] (and unpublished observations).
Trials to address safety, dose and length of therapy
for these agents will be needed.
Should Immunosuppressive Therapy (IST) be
stopped for Relapse?
Abrupt cessation of cyclosporine for early mor-
phologic relapse after T cell-replete HCT has limited
efficacy for diseases other than early phase chronic
myeloid leukemia (CML) and most patients developed
acute GVHD (aGVHD) within 2 weeks [45]. How-
ever, it is generally feasible to stop IST as soon as che-
motherapy is begun. If GVHD emerges later then IST
add back may be necessary. In response to 1 or more of
withdrawal of IST, chemotherapy or donor leukocyte
infusion (DLI), the Seattle group reported a CR rate
of 30% among 307 patients in morphologic relapse,
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gation was 9.5 months if CR was achieved and 2-year
overall survival based on time to relapse was 3%
(\100 days), 9% (100-200 days), and 19% (.200
days). These data call into question the utility of cura-
tive intervention attempts, when morphologic (but not
MRD1) relapses occur before 6 months and certainly
before 3 months; thus, broaching the difficult discus-
sion of palliative care is appropriate.
Should DLI be Used?
Unfortunately, the good results of DLI for
relapsed CML do not generalize to other leukemias;
survival at 2 years after DLI has been dismal to inter-
mediate for AML. Factors in larger studies that were
associated with the best survival (50%-60%) were
DLI in morphologic CR and/or favorable cytogenet-
ics. Female patients or those not in CR but \35%
blasts had survival of 20%, and all others, 9% [47].
It is unclear how these risk factors hold up in the era
of an expanding list of prognostic molecular markers
(eg, FLT3, NPM1, CEBPa).
Although timing and cell dose considerations for
DLI in CML have been well established, the more
rapid tempo of AML relapsemeans that low-dose esca-
lating DLIs are usually unfeasible. Reinduction to
achieve CR is advised and the temporary lymphopenic
state that results may facilitate homeostatic expansion
of DLI. Although granulocyte colony stimulating
factor primed DLI does not prevent aplasia (20% of
patients), some data suggest that granulocyte colony
stimulating factor priming lowers aGVHD rates,
with short courses of cyclosporine ormethotrexate fur-
ther adding to this effect without lessening chronic
GVHD or increasing relapse rates [48]. Others have
used granuloctye macrophage colony stimulating unit
and/or low-dose interferon to try to augment the
immunological graft-versus-leukemia (GVL) effect.
Whether prophylactic or preemptive DLI for
high-risk AML is beneficial might be the subject of
future cooperative group trials. An EBMT pediatric
group used sensitive weekly monitoring for increasing
mixed chimerism (recurrent host hematopoiesis) and
intervened with discontinuation of IST and continued
monitoring until complete chimerism was restored.
For patients not on IST, or when mixed chimerism
progressed after stopping IST, low-dose DLI was ini-
tiated. Although nonrandomized, the analysis showed
36% versus 0% survival, respectively, for those who
did or did not receive DLI, which perhaps provides
some proof of principle [49].
What about Extramedullary Relapse?
Extramedullary AML relapse appears more likely
after prior aGVHD or chronic GVHD compared
with those with marrow relapse, suggesting that
GVL effects are more likely in the marrow. Patientswith extramedullary relapse have better response to
combined local and systemic therapy and improved
survival compared with those with marrow relapse
[50]. Therefore, local therapy should not be over-
looked when extramedullary disease is present during
plans for reinduction chemotherapy, DLI, and/or sec-
ond transplant [50,51].
When Should Second Transplant be
Considered?
Most published data on second HCT is becoming
outdated but basic observations are worth reviewing.
The multivariate analysis from an EBMT study of sec-
ond allo-HCT (N 5 177, 50% with AML) showed
better 5-year survival for: relapse .292 days after first
HCT, CR at second HCT, TBI with second HCT,
and aGVHD after first and second HCT [52]. Eapen
et al. [53] reported overall TRM of 42% and LFS
28% at 5 years; multivariate analyses showed improved
outcomes for children (\20 years) and relapses
.6 months from first HCT [53]. High-dose TBI/Cy
can be safely given before second HCT in pediatric
AML at least 6 months after high-dose Bu/Cy [54].
Although generally less relevant now, allogeneic after
initial autologous HCT can result in 46% 2-year
disease-free survival for AML, and favorable risk fac-
tors were: age\17 years, being in CR, and receiving
TBI for the second HCT [55]. These data are helpful
to consider because relapse is generally higher after
RIC. However, children who have received high-
dose TBI will need RIC options that currently include
FLU and Bu, FLU/melphalan, or FLU/treosulfan.
Augmentation of RIC platforms while preserving
acceptable toxicity might involve replacing FLU with
clofarabine, or adding radiolabeled monoclonal anti-
bodies for better marrow targeting.
The notion that a different donor for second HCT
may provide greater GVL has not been confirmed with
the caveat than most studies have been underpowered
to address this question.
SUMMARYAND FUTURE DIRECTIONS
There are no standard approaches and only limited
information on therapeutic interventions other than
DLI to treat relapse after HCT. Studies are needed
to further characterize the significance of MRD, and
particularly whether intervention can reverse the prog-
nosis of pretransplant MRD1 AML. Relapse prophy-
laxis strategies are being explored in the form of
targeted conditioning, minimally toxic posttransplant
chemoprophylaxis, second transplants, and other
approaches not discussed here due to time constraints.
The latter include natural killer cell infusions, and
naive T cell-depleted first HCT to try and abrogate
aGVHD, thereby providing a feasible platform for
natural killer, natural killer T, and central memory
S38 Biol Blood Marrow Transplant 18:S33-S39, 2012P. A. Carpenter et al.T cells with potential to induce GVL hopefully unen-
cumbered by high-dose steroids. One current draw-
back is the lack of large numbers of defined target
antigens that can be exploited [56,57].AUTHOR CONFLICTOF INTEREST
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